

**ASX ANNOUNCEMENT****Updated Xanamem Clinical Development Program**

- Additional Xanamem studies in planning or underway, following successful \$16.5m capital raise
- Studies will expand the clinical data-set on Xanamem and value-add to prospective partnering discussions
- The program of studies includes target occupancy, higher dose safety and toxicology studies
- Market expansion opportunities through new clinical indications for Xanamem under evaluation
- A number of these studies report out around the same time as XanADu in Q2 2019, providing invaluable data for the future development of Xanamem

**Sydney 30 July 2018.** Actinogen Medical ASX: ACW ('ACW' or 'the Company') is pleased to announce a significant expansion of its Xanamem clinical development program following the successful completion of the recent capital raise. The Company raised \$16.5m through an institutional placement and share purchase plan. These funds will be used to undertake a number of important additional studies to expand the growing data-set on Xanamem. This will substantially value-add to the Company's ongoing discussions with potential partners on the future clinical development and commercialisation of Xanamem.

**Updated Clinical Development Program**

The updated development program includes:

**A Target Occupancy Study.** A highly specialised study that aims to accurately demonstrate the effect different doses of Xanamem has on the 11B-HSD1 enzyme in the human brain. The initial work on the Target Occupancy Study is already underway, with the results anticipated in Q2 2019, in-line with the expected top-line results for XanADu.

**A higher dose safety study.** To expand the safety data-set for Xanamem and allow for higher doses of the drug to be used, if required, including in non-Alzheimer's applications. This human study is expected to initiate in Q4 2018.

**Additional safety toxicology studies.** To allow for longer treatment periods, as normally required by global regulatory authorities in the development of any drug. Likewise, these studies are expected to initiate in Q4 2018.

**Market expansion opportunities**

Multiple promising new clinical indications for Xanamem are under evaluation, to expand the potential use of Xanamem beyond Alzheimer's. These indications include a number of conditions considered to be associated with cortisol induced cognitive impairment, such as diabetes, depression, Parkinson's disease, schizophrenia, as well as conditions like post-traumatic stress disorder (PTSD) and post myocardial infarction. Timing for the initiation of these studies is dependent on the outcome of an ongoing review of all potential indications that will complete in the next few months.

"We are delighted to have successfully raised the necessary capital to strengthen and accelerate our development programs for Xanamem, and we look forward to initiating these important studies and to providing updates on the progress over the next 12 months. All these studies will provide for an invaluable data-set to enhance the value of Xanamem to prospective future development partners." said Dr Bill Ketelbey CEO of Actinogen Medical.

## ENDS

### Actinogen Medical

Dr. Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: [bill.ketelbey@actinogen.com.au](mailto:bill.ketelbey@actinogen.com.au)

 [@BillKetelbey](https://twitter.com/BillKetelbey)

### Media Enquires

Imogen Conyers

Media & Capital Partners

M: +61 405 191 257

E: [imogen.conyers@mcpartners.com.au](mailto:imogen.conyers@mcpartners.com.au)

### About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy, with its first clinical application in Alzheimer's disease, a condition with a multi-billion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

### About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

### About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

**Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.**